Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 1;37(3):278-288.
doi: 10.1097/MOP.0000000000001459. Epub 2025 Mar 28.

Why some and not others? Understanding vascular phenotypes in genetic developmental lung diseases

Affiliations
Review

Why some and not others? Understanding vascular phenotypes in genetic developmental lung diseases

Lea C Steffes et al. Curr Opin Pediatr. .

Abstract

Purpose of review: Pulmonary vascular disease is more common in certain genetic developmental lung disorders. This review synthesizes clinical descriptions, molecular analyses, and single-cell transcriptional data to build a conceptual framework to help understand why some variants affect the vasculature while others primarily manifest with parenchymal disease.

Recent findings: Genes predominantly expressed in endothelial and mesenchymal compartments ( TBX4 , FGF10 , FOXF1 , KDR ) commonly present with both parenchymal and pulmonary vascular disease, while epithelial-restricted genes ( SFTPC , ABCA3 , NKX2.1 ) typically manifest as parenchymal disease. Single-cell analyses reveal that compartment-specific expression patterns correlate with clinical phenotypes. Phenotypic variability, even among individuals sharing identical variants, suggests complex interactions between genetic modifiers, epigenetic factors, and developmental processes that remain poorly understood.

Summary: Compartment-specific gene expression patterns fundamentally underlie the differential presence of vascular phenotypes in DEVLDs. Genetic advances and single cell technologies have revolutionized our understanding of these disorders, but we are in the early stages of translating this knowledge into meaningful clinical advances. Future efforts must bridge this gap to transform clinical care from supportive to targeted, disease-modifying treatment based on cell-specific molecular mechanisms.

Keywords: developmental lung disease; gene expression; genotype–phenotype correlation; pulmonary vascular disease; single-cell transcriptomics.

PubMed Disclaimer

References

    1. Laenger FP, Schwerk N, Dingemann J, Welte T, Auber B, Verleden S, et al. Interstitial lung disease in infancy and early childhood: a clinicopathological primer. European Respiratory Review. 2022-March-09;31(163). - PMC - PubMed
    1. Deutsch GH, Young LR, Deterding RR, Fan LL, Dell SD, Bean JA, et al. Diffuse Lung Disease in Young Children. American Journal of Respiratory and Critical Care Medicine. 2012-December-20;176(11). - PMC - PubMed
    1. Fan LL, Dishop MK, Galambos C, Askin FB, White FV, Langston C, et al. Diffuse Lung Disease in Biopsied Children 2 to 18 Years of Age. Application of the chILD Classification Scheme. Annals of the American Thoracic Society. 2015-October-08;12(10). - PMC - PubMed
    1. Varghese NP, Austin ED, Galambos C, Mullen MP, Yung D, Guillerman RP, et al. An interdisciplinary consensus approach to pulmonary hypertension in developmental lung disease. European Respiratory Journal. 2024-September-26;64(3). - PMC - PubMed
    2. ** This novel multidisciplinary consensus framework addresses pulmonary hypertension in developmental lung disorders (DEVLD-PH) beyond bronchopulmonary dysplasia and congenital diaphragmatic hernia, establishing new recommendations for genetic evaluation, diagnostics, and interdisciplinary management to optimize infant outcomes.

    1. Temple SEL, Ho G, Bennetts B, Boggs K, Vidic N, Mowat D, et al. The role of exome sequencing in childhood interstitial or diffuse lung disease. Orphanet Journal of Rare Diseases 2022. 17:1. 2022-September-09;17(1). - PMC - PubMed